hackint0sh/New-Dataset huggingface dataset:
The anticipated results promise to expand our understanding of the potential for new technologies in cognitive assessment and intervention. Moreover, by employing machine learning analysis of the data collected through VibrantMinds, we aim to develop a taxonomy that correlates game complexity and player performance with conventional clinical instruments for assessing cognitive status and functioning. conditions: Mild Cognitive Impairment conditions: Dementia conditions: Alzheimer Disease conditions: Aging studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The experimental group will receive VibrantMinds, which consists of sessions with serious computer games in addition to the standard care, whilst the control group will receive the standard of care used at the healthcare facilities. primaryPurpose: DEVICE_FEASIBILITY masking: DOUBLE maskingDescription: Random allocation, 1:1 ratio by a computer-based randomizer whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 122 type: ESTIMATED name: VibrantMinds measure: Cognition - Global measure: Depression measure: Agitation measure: Occupational Performance measure: Engagement measure: Affect sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: CapitalCare Group Inc Facilities status: RECRUITING city: Edmonton zip: T5J 3M9 country: Canada name: Adriana Rios Rincon, PhD, R.OT role: CONTACT phone: 7804921728 email: aros@ualberta.ca lat: 53.55014 lon: -113.46871 hasResults: False
nctId: NCT06366854 id: IRAS: 332418 briefTitle: UK ANDROMEDA-Shock-2 RCT overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-04-30 date: 2028-04-30 date: 2024-04-16 date: 2024-04-16 name: Guy's and St Thomas' NHS Foundation Trust class: OTHER name: Pontificia Universidad Catolica de Chile name: University of Rotterdam, The Netherlands briefSummary: The purpose of the trial is to test if a strategy of resuscitation guided by capillary refill time and individualised clinical hemodynamic phenotyping can improve important clinical outcomes within 28 days in septic shock patients compared to usual care. conditions: Septic Shock studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 25 type: ESTIMATED name: Personalised fluid and haemodynamic resuscitation measure: hospital mortality measure: organ support measure: length of stay measure: mortality measure: vital organ support measure: length of stay sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06366841 id: 6439 briefTitle: Stigma and Psychological profilE in REctal-anal caNcer pAtients acronym: SERENA overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-04-30 date: 2026-04-30 date: 2024-04-16 date: 2024-04-16 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER briefSummary: In 2022, Italy is estimated to have 48,100 cases of colon-rectum cancer. Locally advanced mid-lower rectal cancers require preoperative chemo-radiotherapy with fluoropyrimidine. The diagnosis and treatment of rectal cancer have a significant impact on patients' well-being, causing physical and psychological distress. Symptoms such as abdominal pain, fatigue, diarrhea, are commonly reported. While distress levels have been examined before, the relationship between other aspects of the patient experience, such as psychosocial factors, stigma, temperament and personality, alexithymia, have not been extensively explored. Colorectal cancer is associated with specific socially stigmatized challenges. Stigmatization is defined as societal identification of an individual as abnormal and worthy of separation, leading to discrimination and loss of social status. Rectal cancer patients may perceive high levels of stigma and blame due to factors such as defecation-related symptoms, colonoscopy or rectal examinations, physical limitations, loss of work ability and the use of colostomy or ileostomy. Anal cancer, although traditionally surrounded by social stigma, is gaining awareness worldwide due to increasing diagnoses. In other forms of cancer, stigma has been linked to personality traits. Given the characteristics related to the illness and the profile of rectal and anal cancer patients, it is important to assess the psychological traits and psychological resources, also in order to establish tailored psychological pathways during the disease trajectory that comprehend chemoradiations and possible subsequent surgery. Currently, there is no documented data on the relationship between stigma, and psychological profiles in rectal and anal cancer patients. Aim of this protocol is to evaluate the stigma, and psychopathological profile in rectal and anal cancer patients and to evaluate changes in those variables over time. conditions: Rectal Cancer conditions: Anal Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 148 type: ESTIMATED name: Psychological tests administration measure: Evaluation of rectal and anal cancer stigma measure: Evaluation of psychological characteristics in rectal and anal cancer measure: Temperament Evaluation of Memphis, Pisa, Paris and San Diego-autoquestionnaire brief version measure: Toronto Alexithymia Scale measure: EORTC QLQ - CR29 and EORTC QLQ-ANL27 sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione Policlinico Universitario A. Gemelli IRCCS city: Roma zip: 00168 country: Italy lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06366815 id: 4619 briefTitle: phenotypeS in Non Ambulant Duchenne Muscular Dystrophy acronym: GUP21003 overallStatus: RECRUITING date: 2022-08-30 date: 2024-09-30 date: 2025-12-30 date: 2024-04-16 date: 2024-04-16 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER briefSummary: The aims of the study are to prospectively collect information on several aspects of function in non-ambulant DMD patients by using a structured battery of tests including motor, respiratory and cardiac function conditions: Duchenne Muscular Dystrophy conditions: Natural History conditions: Motor Function; Retardation studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 250 type: ESTIMATED name: Different Phenotypes of non ambulant patients with Duchenne Muscular Dystrophy measure: motor function measure: respiratory function measure: cardiac function measure: identify patterns of severity and of progression related to differnt genotypes sex: MALE minimumAge: 8 Years maximumAge: 35 Years stdAges: CHILD stdAges: ADULT facility: IRCCS catholic univeristy status: RECRUITING city: Roma country: Italy name: Marika Pane, prof role: CONTACT phone: 0038063015 phoneExt: 6742 email: marika.pane@policlinicogemelli.it name: Daniela Leone role: CONTACT phone: 00390630158821 email: daniela.leone@policlinicogemelli.it lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06366802 id: Prognosis model-MM09 briefTitle: Cohort Construction and Prognostic Model Construction for Multiple Myeloma overallStatus: ACTIVE_NOT_RECRUITING date: 2022-05-03 date: 2027-05-02 date: 2027-05-02 date: 2024-04-16 date: 2024-04-16 name: The First Affiliated Hospital of Soochow University class: OTHER briefSummary: Multiple myeloma (MM) is a disease caused by malignant plasma cell proliferation disorder. Survival outcomes continue to vary widely even within uniformly treated clinical trial populations. How to construct a clinical prognosis model of MM through real-world data to guide the selection of treatment options, standardize patient management, and improve survival expectations, is a major problem that needs to be solved urgently. It is necessary to build an MM-specific cohort in China to comprehensively understand the characteristics of MM patients, explore treatment options, and improve prognostic factors for survival outcomes. conditions: Multiple Myeloma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 1000 type: ESTIMATED measure: Overall survival measure: Progression free survival(PFS) sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Soochow University city: Suzhou state: Jiangsu zip: 215006 country: China lat: 31.30408 lon: 120.59538 hasResults: False
nctId: NCT06366789 id: ZE46-0134-0002 id: CT-2024-CTN-00161-1 type: OTHER domain: Therapeutic Goods Administration briefTitle: Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-09 date: 2027-12 date: 2024-04-16 date: 2024-04-16 name: Eilean Therapeutics class: INDUSTRY briefSummary: This is a clinical study aiming to assess pharmacokinetics, pharmacodynamics and preliminary efficacy of ZE46-0134 in patients with FLT3 mutated Relapsed or Refractory Acute Myeloid Leukemia conditions: AML With Gene Mutations studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: dose escalation and dose optimization study primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: ZE46-0134 measure: The incidence of DLTs measure: Incidence of AE/SAE measure: Incidence of clinically significant abnormal laboratory results measure: Incidence of abnormal clinically significant ECG results measure: Number of patients with AEs of Grade ≥ 3 measure: Number of treatment-related deaths measure: Plasma Cmax measure: Plasma Css measure: Plasma Cmin measure: Plasma AUC measure: Number of patients attaining any type of Complete Remission (CR, CRh, CRi) by Cycle 6 measure: Number of patients attaining CR by Cycle 6 measure: Number of patients attaining response (CR, CRh, CRi, MLFS) by Cycle 6 measure: Proportion of patients who became FLT3 ITD and TKD undetectable measure: Number of patients with Genomic or proteomic abnormalities sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Linear Clinical Research Ltd city: Perth state: Nedlands, WA zip: 6009 country: Australia name: Carolyn Grove, Prof role: CONTACT lat: -31.95224 lon: 115.8614 hasResults: False
nctId: NCT06366776 id: 23-278 briefTitle: Emulated Study of Vitamin D Correction vs Non-Correction overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-06 date: 2024-12 date: 2024-04-16 date: 2024-04-16 name: The Cooper Health System class: OTHER name: Won Sook Chung Foundation briefSummary: * This is a single-site retrospective electronic chart review of Cooper Health System Inpatients and Outpatients from 2008 through 2023 aged eighteen years or older. This review is designed as an emulation of a randomized clinical trial with a nonrandomized database.
* The primary objectives are to compare healthcare costs and healthcare utilization between subjects who have corrected low vitamin D levels and those without corrected low vitamin D levels. conditions: Vitamin D Deficiency studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 9000 type: ESTIMATED measure: Ten healthcare costs parameters among the corrected Treatment Group and the uncorrected Control Group A. measure: Ten healthcare utilization parameters among the corrected Treatment Group and the uncorrected Control Group A. measure: Ten healthcare costs parameters among patients with sufficient vitamin D levels (Control Group B). measure: Ten healthcare utilization parameters among patients with sufficient vitamin D levels (Control Group B). sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06366763 id: ChengduUTCMvs5 briefTitle: Comparative Clinical Efficacy Between Multi-layer Bandage Pressure Therapy and Gradient Pressure Elastic Stocking Treatment After Endovenous Radiofrequency Ablation overallStatus: RECRUITING date: 2023-08-01 date: 2024-08-01 date: 2024-08-01 date: 2024-04-16 date: 2024-04-16 name: Chengdu University of Traditional Chinese Medicine class: OTHER briefSummary: Objective: To assess the clinical efficacy of different compression methods within 48 hours after endovenous radiofrequency ablation (RFA) in terms of great saphenous vein closure rate, postoperative complications, quality of life, time to return to normal work, and patient satisfaction. conditions: Vascular Diseases, Peripheral conditions: Venous Insufficiency of Leg conditions: Varicose Veins of Lower Limb studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Among the 210 patients included in the study (82 males, 128 females; average age of 59 years), 7 patients were lost to follow-up, and the remaining patients completed the treatment and follow-up.To assess the clinical efficacy of different compression methods within 48 hours after endovenous radiofrequency ablation (RFA) in terms of great saphenous vein closure rate, postoperative complications, quality of life, time to return to normal work, and patient satisfaction. primaryPurpose: TREATMENT masking: NONE count: 210 type: ESTIMATED name: Questionnaires measure: Pain after radiofrequency ablation measure: Bleeding after radiofrequency ablation measure: Tension blisters after radiofrequency ablation measure: The rate of occlusion of treated vein post-procedure measure: Quality of life score using the Chronic Venous Insufficiency Questionnaire(CIVIQ-14) measure: Clinical Change using Venous Clinical Severity Score (VCSS) sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital of Chengdu University of Traditional Chinese Medicine status: RECRUITING city: Chengdu state: Sichuan zip: 610000 country: China name: Chunshui He, Doctor role: CONTACT phone: 86-18981885601 email: chunshuihe@msn.com name: Qiqi Wangqiqi, Master role: CONTACT phone: 86-15184495605 email: 285510746@qq.com lat: 30.66667 lon: 104.06667 hasResults: False
nctId: NCT06366737 id: CEBD-CU-2024-03-02 briefTitle: En-mass Retraction by Lingual Retractor Versus Clear Aligner Appliances overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-12 date: 2025-03 date: 2024-04-16 date: 2024-04-16 name: Cairo University class: OTHER briefSummary: en-mass retraction by lingual retractor versus clear alighner therapy conditions: Maxillary Prognathism studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: Lingual Retractor Appliance name: clear aligner measure: patient satisfaction ( time , cost , quality) measure: inclination of upper anterior teeth sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Faculty of Dentistry city: Cairo country: Egypt name: zainab abdulrhman role: CONTACT phone: 00201092445775 email: zeinab_mohammed@dentistry.cu.edu.eg lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06366724 id: 2024P000087 briefTitle: LIFT: Life Improvement Trial acronym: LIFT overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2026-03 date: 2026-06 date: 2024-04-16 date: 2024-04-16 name: Brigham and Women's Hospital class: OTHER name: Open Medicine Foundation briefSummary: The LIFT will be conducted at Brigham and Women's Hospital (BWH) of Harvard Medical School, focusing on the effect of Pyridostigmine (Mestinon) and Low-Dose Naltrexone (LDN) in subjects aged 18-65 meeting the Canadian consensus criteria (CCC) for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) as well as having specifically Orthostatic Intolerance.
This double-blind, placebo-controlled study will involve 160 participants randomized into one of four possible groups: Pyridostigmine/LDN (40), Pyridostigmine/Placebo (40), LDN/Placebo (40), Placebo/Placebo (40). The dose of Pyridostigmine will be carefully titrated from 30mg to 60mg three times a day, and the dose of LDN will be titrated from 1.5 mg to 4.5 mg once daily.
The time commitment for the participant is approximately three (3) months, and during this time, there will be three (3) in-person visits to BWH and four (4) virtual visits. Study procedures will include two (2) submaximum cardiopulmonary exercise tests, questionnaires (virtually completed), and blood and urine collection. We will be recruiting from the BWH Dyspnea Clinic as well as the Open Medicine Foundation (OMF) StudyME Registry and anticipate the entire trial will take two (2) years to complete.
The LIFT represents a significant endeavor to improve treatment options for ME/CFS patients and contribute to the broader understanding of this debilitating condition. conditions: ME/CFS studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: FACTORIAL interventionModelDescription: Randomized factorial group double-blinded placebo-controlled trial primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: The Mass General Brigham Investigational Drug Services (IDS) will be responsible for randomizing the four arms. The rest of the study staff and collaborators will be blinded as well as the participant. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 160 type: ESTIMATED name: Pyridostigmine name: Low-Dose Naltrexone name: Placebo measure: Functional Capacity measure: Physiologic Response - Oxygen Uptake Efficiency Slope (OUES) measure: Physiologic Response - Oxygen Utilization (VO2) measure: Physiologic Response - Heart Rate Recovery (HRR) measure: Post-Exertional Malaise measure: PROMIS-29-Pain measure: Daily Activity measure: Heart Rate Variability measure: Blood Oxygen measure: Resting Heart Rate measure: DANA Brain Vital-Simple Reaction Time (SRT) measure: DANA Brain Vital-Procedural Reaction Time (PRT) measure: DANA Brain Vital-Memory Search (MS) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06366711 id: 23/BW/MAT/NO/754 briefTitle: Remote Telemedicine Fetal Monitoring Feasibility Study overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-08 date: 2024-10 date: 2024-04-16 date: 2024-04-16 name: Birmingham Women's NHS Foundation Trust class: OTHER_GOV name: GE Healthcare name: Nestmedic S.A. briefSummary: During pregnancy, certain conditions may arise that mean regular monitoring of both mother and baby are needed to ensure timely interventions and avoid the need for further treatments. These situations include problems with high blood pressure, obstetric cholestasis (characterised by liver-related itchiness), preterm premature rupture of membranes (PPROM), and a history of stillbirth. Monitoring typically involves assessing the mother's blood pressure and urine, recording the baby's heart rate over a specific duration, and conducting regular ultrasound scans. Such monitoring can require frequent hospital visits, often multiple times a week, which can be very time consuming. More recently, new technology has emerged, enabling remote monitoring of mother and baby outside of the hospital setting, such as their own home. However, research on these technologies is still very limited.
Our study aims to address this research gap by inviting women with the above conditions to volunteer for home-based monitoring, alongside their routine hospital care. Participants will be divided into three groups: one group will use transducers, attached to the mothers tummy, to capture the baby's heartbeat; another group will use a handheld ultrasound device connected to their mobile phones, allowing them to observe the baby; and a third group will use both devices. All device information will be transmitted securely to the healthcare professional for analysis. The investigators aim to assess the feasibility of conducting remote monitoring of mother and baby, whilst understanding how acceptable the technology is received.
Importantly, the data collected will only be evaluated by the research team and will not be intended to influence patient's current planned antenatal care. Women will receive comprehensive training on the devices. The study will additionally gather feedback from participating women through questionnaires, both at the study's outset and its conclusion, regarding their experiences and emotions related to the research. conditions: Pregnancy, High Risk conditions: Telemonitoring conditions: Telemedicine conditions: Ultrasound conditions: Cardiotocography studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: 15 participants split in to three arms. The sample size has been determined as a pragmatic sample taking into consideration the needs of the feasibility study to meet the stated objectives as well as being achievable within the time and cost constraints of the study. 15 participants will ensure a thorough assessment of the stated objectives. primaryPurpose: DEVICE_FEASIBILITY masking: NONE count: 15 type: ESTIMATED name: Pregnabit Pro device and PregnaOne platform name: Pulsenmore device measure: The number of participants that produce interpretable fetal ultrasound scans for each episode of intermittent home monitoring. measure: The number of participants that produce interpretable antenatal maternal-fetal monitoring cardiotocogram (CTG) traces for each episode of intermittent home monitoring. measure: The number of participants completing the full schedule of home maternal-fetal monitoring episodes. measure: To explore how acceptability and participant views can best be assessed within a future clinical trial using wearable technology at home? measure: The number of women approached who agreed to participate within the study. measure: What are the views of participants and healthcare professionals regarding acceptability of home maternal-fetal monitoring. measure: What are the views of participants and healthcare professional regarding acceptability of home maternal-fetal monitoring. measure: What are the emotions of participants prior to and following usage of home maternal-fetal monitoring. measure: What are the emotions of participants prior to and following usage of home maternal-fetal monitoring. measure: The number of participants with unexpected clinical outcomes detected whilst using home monitoring devices, which warrants patients to attend maternity triage for assessment and/or modification of ones antenatal care. sex: FEMALE minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False